<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04602689</url>
  </required_header>
  <id_info>
    <org_study_id>2004-093-1117</org_study_id>
    <nct_id>NCT04602689</nct_id>
  </id_info>
  <brief_title>Fibrin Glue After ESD for High Risk Patients of Bleeding</brief_title>
  <official_title>Effectiveness of Fibrin Glue to Prevent Bleeding in High-risk Patients After Endoscopic Submucosal Dissection in Gastric Neoplasm : A Prospective Randomized Controlled Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Seoul National University Bundang Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Severance Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Asan Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      It is a prospective randomized controlled study to look for effectiveness of fibrin glue to&#xD;
      prevent bleeding in high-risk patients after endoscopic submucosal dissection in gastric&#xD;
      neoplasm.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Investigators want to observe the bleeding rate after endoscopic submucosal dissection for&#xD;
      gastric tumors in the high-risk group of bleeding (the size of the iatrogenic ulcer is&#xD;
      expected to be 40mm or more, or taking aspirin, antiplatelet drugs, and anticoagulants).&#xD;
&#xD;
      After resection and hemostasis with ESD, Fibrin glue (Greenplast Q™) is applied to the&#xD;
      iatrogenic ulcer at the end of the procedure, and the control group will not be applied.&#xD;
&#xD;
      After that, observe whether there is a difference in the bleeding rate within 48 hours and 4&#xD;
      weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2020</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bleeding after ESD</measure>
    <time_frame>4 weeks</time_frame>
    <description>Number of gastrointestinal bleeding events within 4 weeks after the procedure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Early bleeding after ESD</measure>
    <time_frame>48 hours</time_frame>
    <description>Number of gastrointestinal bleeding events within 48 hours after the procedure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Delayed bleeding after ESD</measure>
    <time_frame>from 48 hours to 4 weeks</time_frame>
    <description>Number of gastrointestinal bleeding events from 48 hours to 4 weeks after the procedure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">254</enrollment>
  <condition>Early Gastric Cancer</condition>
  <condition>Gastric Adenoma</condition>
  <arm_group>
    <arm_group_label>Fibrin glue group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Spread Fibrin glue(Greenplast Q™) at iatrogenic ulcer after gastric ESD</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No intervention after gastric ESD</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human fibrinogen concentrate</intervention_name>
    <description>Spread the Human fibrinogen concentrate/Aprotinin/Thrombin/Calcium chloride hydrate mixture on iatrogenic ulcer after ESD</description>
    <arm_group_label>Fibrin glue group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ECOG performance status 0-1&#xD;
&#xD;
          -  Patients scheduled to undergo ESD due to gastric tumor (dysplasia, early gastric&#xD;
             cancer)&#xD;
&#xD;
          -  Patients who are expected to have an iatrogenic ulcer size of 40mm or more after&#xD;
             endoscopic submucosal dissection, or are taking aspirin, antiplatelet drugs, or&#xD;
             anticoagulants&#xD;
&#xD;
          -  Patients who show adequate patient compliance and have adequate geographic distance&#xD;
             for follow-up observation.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with sensitivity to cow protein or its derived ingredients&#xD;
&#xD;
          -  Patients who had previously undergone partial gastrectomy&#xD;
&#xD;
          -  Patients with early gastric cancer at the site previously undergoing ESD&#xD;
&#xD;
          -  Patients with clinically significant cardiopulmonary disease&#xD;
&#xD;
          -  Patients with active hepatitis, liver disease that is not well controlled by&#xD;
             treatment, or severe liver disorder&#xD;
&#xD;
          -  Patients with severe renal impairment&#xD;
&#xD;
          -  Patients with severe bone marrow dysfunction&#xD;
&#xD;
          -  Patients with severe blood clotting impairment (including hemophilia)&#xD;
&#xD;
          -  Patients with serious neurological or mental illness (e.g. epilepsy or dementia)&#xD;
&#xD;
          -  Patients with reported side effects of contrast media&#xD;
&#xD;
          -  Pregnant and lactating women&#xD;
&#xD;
          -  Patients who have not obtained the informed consent of the patient and guardian&#xD;
&#xD;
          -  Patients who are inadequate for clinical trials as judged by the attending physician&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>84 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eunwoo Lee, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>fellowship</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eunwoo Lee, M.D.</last_name>
    <phone>82-10-9404-9109</phone>
    <email>rfsquid@naver.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Soo-Jeong Cho, M.D., Ph.D.</last_name>
    <phone>82-10-5297-3398</phone>
    <email>crystal522@daum.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>03080</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eunwoo Lee, M.D.</last_name>
      <phone>82-10-9404-9109</phone>
      <email>rfsquid@naver.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>October 20, 2020</study_first_submitted>
  <study_first_submitted_qc>October 20, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 26, 2020</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Seoul National University Hospital</investigator_affiliation>
    <investigator_full_name>Soo-Jeong Cho</investigator_full_name>
    <investigator_title>Clinical associate professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenoma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

